© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Urothelial Carcinoma
Padeliporfin ImPACT Receives Orphan Drug Designation for Upper Tract Urothelial Cancer
April 07, 2021
Drug would mean a nonsurgical treatment option for people with upper tract urothelial cancer.
COVID-19 Vaccines and Innovative Oncology Services for Patients with Urothelial Carcinoma Have Expanded During the Pandemic
April 06, 2021
COVID-19 vaccine is safe — and more than a little advisable — for people with urothelial cancer, says a clinical pharmacist at the VA Pittsburgh Healthcare System.
NCCN Update in Urothelial Bladder Cancer Highlights Checkpoint Inhibitors, Maintenance Therapy
March 26, 2021
The advent of checkpoint inhibitors has altered the treatment landscape in urothelial bladder cancer, said Arlene O. Siefker-Radtke, MD, during last week’s NCCN Conference.
Urothelial Cancer Indications Withdrawn From Two Important Cancer Meds, Tecentriq and Imfinzi
March 12, 2021
After accelerated approval, both drugs fall short of overall survival endpoint. They will stay on the market for other indications.
Padvec Prolongs Survival in Locally Advanced or Metastatic Urothelial Carcinoma
March 11, 2021
New drug may be a treatment option for people with the sixth most common type of cancer.
U.S. Cancer Diagnoses Fell by 50% in 2020 Amid the Pandemic, says NCI Director Sharpless
February 19, 2021
NCI Director Norman Sharpless discussed deferred care, missed screening and his future at the institute in an interview with Managed Healthcare Executive.
SDOH: How They Affect Cancer Rates, Care and Payment
February 17, 2021
Adjustments to payment models are beginning to take social determinants into account.
Otis Brawley: Certain Cancer Screening Tests Have Exacerbated Health Disparities
November 02, 2020
The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.
Otis Brawley: It’s Gotten Better but Problems With Cancer Screening Haven’t Gone Away
October 22, 2020
“Lung cancer screening is a great example of the problem,” says the former chief medical and scientific officer for the American Cancer Society in this third of four-part video series.
Meet the Board: Otis Brawley Talks Health, Racial Disparities, Cancer Screenings and More
September 30, 2020
This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.